4A10
Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (ALL)
Key Facts
About Allterum Therapeutics
Allterum Therapeutics is a private, preclinical-stage biotech founded in 2018 and incubated by Fannin, an early-stage life sciences development group. The company is advancing 4A10, an anti-CD127 monoclonal antibody in-licensed from the National Cancer Institute (NCI), to address critical unmet needs in relapsed/refractory hematologic cancers, particularly pediatric T-cell ALL. With strong academic collaborations, Orphan Drug Designation for its lead program, and non-dilutive grant funding from CPRIT, Allterum is positioned to advance its lead candidate toward clinical trials for a patient population with very poor prognosis and limited treatment options.
View full company profileAbout Allterum Therapeutics
Allterum Therapeutics is a private, preclinical-stage biotech founded in 2018 and incubated by Fannin, an early-stage life sciences development group. The company is advancing 4A10, an anti-CD127 monoclonal antibody in-licensed from the National Cancer Institute (NCI), to address critical unmet needs in relapsed/refractory hematologic cancers, particularly pediatric T-cell ALL. With strong academic collaborations, Orphan Drug Designation for its lead program, and non-dilutive grant funding from CPRIT, Allterum is positioned to advance its lead candidate toward clinical trials for a patient population with very poor prognosis and limited treatment options.
View full company profileAbout Allterum Therapeutics
Allterum Therapeutics is a private, preclinical-stage biotech founded in 2018 and incubated by Fannin, an early-stage life sciences development group. The company is advancing 4A10, an anti-CD127 monoclonal antibody in-licensed from the National Cancer Institute (NCI), to address critical unmet needs in relapsed/refractory hematologic cancers, particularly pediatric T-cell ALL. With strong academic collaborations, Orphan Drug Designation for its lead program, and non-dilutive grant funding from CPRIT, Allterum is positioned to advance its lead candidate toward clinical trials for a patient population with very poor prognosis and limited treatment options.
View full company profile